Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from biotechnology

Marine fungi could help feed the world and fight disease

Fungi are nature’s recyclers and chemists, turning waste into useful products and creating an array of enzymes and compounds. By harnessing this potential through fungal biotechnology (using fungi to develop products and technologies for various applications), we can create sustainable materials, food and processes that help solve global challenges like…

The Conversation

Beyond de-extinction and dire wolves, gene editing can help today’s endangered species

Have you been hearing about the dire wolf lately? Maybe you saw a massive white wolf on the cover of Time magazine or a photo of “Game of Thrones” author George R.R. Martin holding a puppy named after a character from his books.

The Conversation

How Is Moderna’s Stock Performance Compared to Other Biotechnology Stocks?

Moderna has significantly underperformed other biotechnology stocks over the past year, and analysts remain cautious on the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than Double

Analysts are uber bullish on Actuate Therapeutics and PDS Biotechnology stocks for the next 12 months. Here’s why.

Barchart

Designer DNA and Ethical Eating: The Brave New World of Biotech Arrives in the UK

Discover how gene editing and lab-grown meat are revolutionising healthcare and food in 2025, offering personalised treatments and sustainable, ethical meat alternatives.

International Business Times UK

Biotechnology company Regeneron buying 23andMe for $256 million

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection

The Independent UK

Cancer research in the US is world class because of its broad base of funding − with the government pulling out, its future is uncertain

Cancer research in the U.S. doesn’t rely on a single institution or funding stream − it’s a complex ecosystem made up of interdependent parts: academia, pharmaceutical companies, biotechnology startups, federal agencies and private foundations. As a cancer biologist who has worked in each of these sectors over the past three…

The Conversation

Read news from The Economist, FT, and more,
with one subscription

Ghana’s first genetically modified crop: why we created a new cowpea variety, how we tested it and what we found

Cowpea (Vigna unguiculata) is an indigenous and staple crop in sub-Saharan Africa, but it has an enemy: an insect called the legume pod borer (Maruca vitrata). This pest can cause yield losses of more than 80%. The pod borer, originally from south-east Asia, attacks the flowers, pods and seeds.

The Conversation

UP: BSc student ends life in hostel room soon after talking to fiance

A final-year BSc student of biotechnology at Veer Bahadur Singh Purvanchal University allegedly committed suicide by hanging herself in her hostel room soon after talking to her fiance over phone

Dynamite News

How to engineer microbes to enable us to live on Mars

A field known as synthetic biology has become one of the most highly anticipated in science. Its outputs range from golden rice, which is genetically engineered to provide vitamin A, to advances stemming from the Human Genome Project, which successfully mapped the entire human genome. Prominent voices in biotechnology have…

The Conversation

Pharma Frenzy: Volatility Ignites Biotech Sector

Two biotech companies have surged on recent developments, illustrating biotech's volatility and prompting investors to evaluate potential long-term value.

MarketBeat

Public money, private patents? Unravelling India’s opacity over its Covid vaccines

Public money, private patents: Unravelling India’s opacity over its Covid vaccines

Newslaundry

Woolly mice are a first step to resurrecting mammoths, but there’s a very long way to go

US biotechnology company Colossal Laboratories and Biosciences has a radical proposal: it wants to resurrect the woolly mammoth from extinction. In a preprint paper published on March 4, scientists at Colossal report making a significant step towards this objective. They genetically modified the DNA of mice to give them mammoth-like…

The Conversation

The emerging role of AI in complementing human expertise in the early detection of breast cancer

Breast cancer has been a significant global health concern, being most commonly detected cancer in women and contributes to the highest number of cancer-related fatalities among women. Surprisingly, it stands as fourth leading cause of all cancer-related deaths globally. India at the cusp of it, faces a significant burden of…

The Times of India

Get all your
news in one place.

100's of premium titles.
One news app.

USA Today Sports Media Group

Purchasing HeLa Cells: What You Need to Know

HeLa cells, the world's first immortal human cell line, have played a crucial role in advancing scientific research and biotechnology. Derived from the cervical cancer cells of Henrietta Lacks in 1951, HeLa cells have been indispensable in numerous ...

Barchart

This Biotech Penny Stock Is Up 120% This Year. Analysts Think It Can Still Triple From Here in 2025.

With positive results from a clinical trial targeting Type 1 diabetes, Wall Street is feeling hot on this little biotech stock.

StockNews.com

3 Biotech Innovators Advancing Genetic Therapies

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global regulations. Considering the advancements, fundamentally solid biotech stocks Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN) are emerging as top choices for investors seeking transformative opportunities. Read further….

Dynamite News

India emerges as a global leader across key sectors in 2024

The year 2024 marked a pivotal year for India, showcasing its dominance in pharmaceuticals, biotechnology, defense, nuclear energy, space, infrastructure, and emerging technologies like quantum computing, AI, and blockchain. Read further on Dynamite News:

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Healthcare ETFs for Defensive Investing

The healthcare sector is poised for strong growth, driven by aging populations, technological advancements, and increased service demand. Thus, to gain exposure to the healthcare sector, one could capitalize on iShares Biotechnology (IBB), SPDR S&P Health Care Equipment (XHE), and iShares U.S. Medical Devices (IHI). Read on….

Al Jazeera

Russia’s security service says jailed American leaked biotechnology secrets

Eugene Spector, a US citizen born in Russia, has been sentenced to 15 years in a maximum security Russian penal colony.

StockNews.com

3 Healthcare Innovators with Analyst-Endorsed Upside

Healthcare innovators are gaining momentum as they address critical challenges in biotechnology, medical devices, and pharmaceuticals. Amid this backdrop, you might consider keeping an eye on three healthcare innovators, Zoetis (ZTS), Immatics N.V. (IMTX), and Esperion Therapeutics (ESPR), which have robust upside potential. Read on….

Barchart

How Is Bio-Techne’s Stock Performance Compared to Other Biotechnology Stocks?

Bio-Techne has underperformed the biotechnology industry over the past year, but analysts are highly optimistic about the stock’s prospects.

StockNews.com

3 High-Growth Biotech Stocks to Watch

Amid the growing innovations, emphasis on enhanced treatment alternatives, and rapid AI adoption, the biotechnology industry is poised for solid long-term growth. Thus, investors could consider adding high-growth biotech stocks MannKind (MNKD), Amicus Therapeutics (FOLD), and Esperion Therapeutics (ESPR) to their watchlist. Continue reading.

StockNews.com

3 Healthcare ETFs for a Resilient Portfolio

With benefits like diversified exposure, resilience, and relatively stable growth, healthcare ETFs present impressive opportunities for investors. Therefore, it could be wise to buy solid healthcare ETFs like First Trust Health Care AlphaDEX (FXH), iShares Biotechnology (IBB), and iShares U.S. Medical Devices (IHI) to build a resilient portfolio. Read more.

StockNews.com

3 Emerging Biotech Stocks Developing Breakthrough Therapies

The biotechnology industry is witnessing groundbreaking advancements in genomics, personalized medicine, and gene editing, propelling the sector toward a future of more precise and effective therapies. As a result, fundamentally robust biotech stocks Harmony Biosciences Holdings (HRMY), Treda Pharmaceuticals (TRDA), and Puma Biotechnology (PBYI) could be wise picks. Read further.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.